Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 100+250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glaxosmithkline pharma a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 25+62,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

ratiopharm gmbh - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 250+100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glenmark arzneimittel gmbh - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 250+100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 100+250 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 25+62,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 250+100 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

viatris limited - atovaquon, proguanilhydrochlorid - filmovertrukne tabletter - 250+100 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.